Anpac Bio-Medical Partnering with International Medical Institutions for Unprecedented 50,000 Patient Esophageal Cancer Study

Anpac Bio-Medical Partnering with Zhengzhou, Fu Dan & Other International Medical Institutions for Unprecedented 50,000 Patient Esophageal Cancer Study

 Sacramento, CA: Dr. Chris Yu, Chief Executive Officer of international life sciences corporation Anpac Bio-Medical Science Company based in Sacramento, CA and Shanghai China, announced today the company is partnering with Asia’s largest medical institution, the First Affiliated Hospital of Zhengzhou University (FAHZU), the prestigious Fudan University (FU), and three other medical institutions, to launch the largest Esophageal Cancer study to date in the world. Over 50,000 patients across Asia – including individuals deemed “high risk” — will be screened, using Anpac Bio’s “Cancer Differentiation Analysis” (CDA) technology, in an effort to identify the disease at its earliest stages.

Esophageal cancer (EC) is the eighth-most common cancer globally, with 456,000 new cases annually. However, EC rates vary widely among countries, with about half of all cases occurring in China; greater than 70% of all newly diagnosed EC cases worldwide.

Early EC detection is particularly difficult for clinicians, because the cancer does not have an easily discernable “Biomarker”; and patients rarely seek treatment until after symptoms persist, and the disease has progressed to “late stage” (Stage 3 or 4). Subsequently, the five-year EC survival rate is currently below 20%. But research indicates if EC is caught and treated in its earliest stages, patient five-year survival rate increases/improves exponentially.

Therefore, FAHZU, FU, and other respected Asian medical institutions are partnering with Anpac Bio to screen 50,000 individuals, identify potential EC patients, and then immediately treat the patients; measuring their progress and five-year survival rates throughout the mass study.

Described in Nobel Prize Laureate Summit on Biomedical Science (NPLS) publications as, “game changing,” Anpac Bio’s CDA technology and medical devices effectively reinvent early cancer screening and detection. By analyzing simple, in vitro, “blood biopsies”, and applying Anpac’s multi-level, multi-parameter, diagnostic algorithms, Anpac’s CDA technology identifies cancer with measurably greater sensitivity, specificity, and accuracy than most current, conventional screening/diagnostic methods. Comprehensive research validity data from nearly 25,000 cases to date indicate Anpac’s CDA diagnostics far exceed existing or competing technologies — revealing a sensitivity and specificity rate range of 75%-90% for over 10 different types of cancer, with the ability of early stage detection for most of them. And it does so without any harmful side effects in patients; generating far fewer “false positives”; and at a cost substantially lower than traditional testing.

“We are very proud to partner with these highly-respected medical institutions in this unprecedented, mass Esophageal Cancer study,” states Dr. Yu. “By using Anpac’s CDA technology, our medical and educational partners can identify Esophageal cancer patients far earlier than through traditional screening methods. And if the disease is caught early and treated, the patient has a significantly better survival rate. Many lives will be saved through this 50,000 patient study; and we are honored to a be a member organization in this effort.”

For more information, please check: www.AnpacBio.com.

Contact: Drisha Leggitt: 916-206-2553 or Drisha_Leggitt@Anpac.cn